New hope for Tough-to-Treat myeloma: experimental drug shows promise

NCT ID NCT04083534

Completed Disease control Sponsor: Regeneron Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new drug called REGN5459 in 43 people with multiple myeloma that had returned or stopped responding to other treatments. The drug works by helping the immune system attack cancer cells. The main goals were to check safety and find the best dose, and to see how well it shrinks tumors.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for REFRACTORY MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma refractory plasma cell neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

REFRACTORY MULTIPLE MYELOMA RELAPSED MULTIPLE MYELOMA

Contacts and locations

Show contact details

Locations

Regeneron Study Site

Indianapolis, Indiana, 46202, United States
Regeneron Study Site

Ann Arbor, Michigan, 48109, United States
Regeneron Study Site

Rochester, Minnesota, 55905, United States
Regeneron Study Site

New York, New York, 10029, United States
Regeneron Study Site

Dallas, Texas, 75390, United States
Regeneron Study Site

Houston, Texas, 77030, United States
Regeneron Study Site

Milwaukee, Wisconsin, 53226, United States